Cure My Disease

Don't miss your cure!

 Log in / Sign up

Daily aspirin in early pregnancy may prevent dangerous pre-eclampsia

NCT ID NCT01729468

Completed Prevention Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking a low-dose aspirin (160 mg) each night, starting before 16 weeks of pregnancy, could prevent pre-eclampsia and small babies in first-time mothers at high risk. Over 1,100 women with abnormal blood flow in the uterine artery were randomly assigned to aspirin or a placebo until 34 weeks. The goal was to see if this simple, safe drug could reduce serious pregnancy complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Aspirin (low-dose, 160 mg per day)
What this could lead to
If effective, this could offer a simple, low-cost way to prevent serious pregnancy complications like pre-eclampsia and restricted fetal growth in high-risk first-time mothers.
What could go wrong
The trial is completed, but results may not apply to all women or pregnancies. Aspirin carries a small risk of bleeding, and the benefit depends on strict early timing and correct dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRA-UTERINE GROWTH RESTRICTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction prevention target preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRA-UTERINE GROWTH RESTRICTION PRE-ECLAMPSIA

Contacts and locations

Locations

  • Cabinet Mosaïque Santé

    La Chaussée-Saint-Victor, 41260, France

  • Centre de dépistage PRIMA FACIE, Hôpital Necker, APHP

    Paris, 75014, France

  • Service de Gynécologie-Obstetrique, Centre Olympe de Gouges, CHRU de Tours

    Tours, 37044, France

  • Service de Gynécologie-Obstétrique, Groupe Hospitalier Pellegrin, CHRU de Bordeaux

    Bordeaux, 33000, France

  • Service de Gynécologie-Obstétrique, HFME, Hospices Civils de Lyon

    Bron, 69677, France

  • Service de Gynécologie-Obstétrique, Hôpital Arnaud de Villeneuve, CHRU de Montpellier

    Montpellier, 34295, France

  • Service de Gynécologie-Obstétrique, Hôpital Carémeau, CHRU de Nîmes

    Nîmes, 30029, France

  • Service de Gynécologie-Obstétrique, Hôpital Paule de Viguier, CHU de Toulouse

    Toulouse, 31059, France

  • Service de Gynécologie-Obstétrique, Hôpital Porte Madeleine, CHR d'Orléans

    Orléans, 45032, France

  • Service de Gynécologie-Obstétrique, Hôpital d'Estaing, CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • Service de Gyénécologie-Obstétrique, Hôpital Jeanne de Flandre, CHRU de Lille

    Lille, 59037, France

  • Service de gynécologie-obstétrique, CHR Le Mans

    Le Mans, 72037, France

  • Service de gynécologie-obstétrique, Hôpital Couple Enfant, CHRU de Grenoble

    Grenoble, 38043, France

  • Service de gynécologie-obstétrique, Hôpital Mère-Enfant, CHRU de Nantes

    Nantes, 44093, France

  • Service de gynécologie-obstétrique, Maison de la Femme de la Mère et de l'Enfant, CHU de Fort de France

    Fort-de-France, 97261, Martinique

  • Service de gynécologie-obstétrique, Polyclinique de l'Atlantique

    Nantes, 44819, France

  • Service de gynécologie-obstétrique, Polyclinique du PARC

    Caen, 14052, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.